In a surprise move, the US Food and Drug Administration (FDA) has now reversed its decision to deny the advancement of the biologics license application (BLA) for Moderna’s new flu shot candidate, mRNA-1010.
In last week’s shocking refusal-to-file letter (RTF), the FDA’s Center for Biologics Evaluation and Research (CBER)